Metlay J P, Witmer-Pack M D, Agger R, Crowley M T, Lawless D, Steinman R M
Rockefeller University, New York, New York 10021.
J Exp Med. 1990 May 1;171(5):1753-71. doi: 10.1084/jem.171.5.1753.
Hybridoma fusions with hamster hosts were undertaken to generate mAbs to mouse spleen dendritic cells. Two mAb were obtained and used to uncover the distinct integrins of these APC. One, 2E6, bound a determinant common to all members of the CD11/CD18 family, most likely the shared 90 kD CD18 beta chain. 2E6 immunoprecipitated the characteristic beta 2 integrin heterodimers from lymphocytes (p180, 90; CD11a) and macrophages (p170,90; CD11b), but from dendritic cells, a p150,90 (presumably CD11c) integrin was the predominant species. 2E6 inhibited the binding function of the CD11a and CD11b integrins on B cells and macrophages in appropriate assays, but 2E6 exerted little or no inhibition on the clustering of dendritic cells to T cells early in primary MLR, suggesting a CD11/CD18-independent mechanism for this binding. The second mAb, N418, precipitated a 150, 90 kD heterodimer that shared the 2E6 CD18 epitope. This N418 epitope may be the murine homologue of the previously characterized human CD11c molecule, but the epitope was only detected on dendritic cells. N418 did not react with peritoneal macrophages, anti-Ig-induced spleen B blasts, or bulk lymph node cells. When used to stain sections of spleen, N418 stained dendritic cells in the T-dependent areas, much like anti-class II mAbs that were also generated in these fusions. In addition, N418 revealed nests of dendritic cells that punctuated the rim of marginal zone macrophages between red and white pulp. This localization positioned most dendritic cells at regions where arterial vessels and T cells enter the white pulp. We conclude that the p150, 90 heterodimer is the major beta 2 integrin of spleen dendritic cells, and we speculate that it may function to localize these APC at sites that permit access to the recirculating pool of resting T cells.
为了产生针对小鼠脾脏树突状细胞的单克隆抗体(mAb),进行了用仓鼠宿主的杂交瘤融合实验。获得了两种单克隆抗体,并用于揭示这些抗原呈递细胞(APC)的不同整合素。一种是2E6,它结合CD11/CD18家族所有成员共有的一个决定簇,最有可能是共享的90kD CD18β链。2E6从淋巴细胞(p180,90;CD11a)和巨噬细胞(p170,90;CD11b)中免疫沉淀出特征性的β2整合素异二聚体,但从树突状细胞中,一种p150,90(可能是CD11c)整合素是主要类型。在适当的实验中,2E6抑制了B细胞和巨噬细胞上CD11a和CD11b整合素的结合功能,但在初次混合淋巴细胞反应(MLR)早期,2E6对树突状细胞与T细胞的聚集几乎没有抑制作用,这表明这种结合存在一种不依赖CD11/CD18的机制。第二种单克隆抗体N418沉淀出一种150,90kD的异二聚体,它与2E6的CD18表位相同。这个N418表位可能是先前鉴定的人类CD11c分子的小鼠同源物,但该表位仅在树突状细胞上被检测到。N418不与腹腔巨噬细胞、抗Ig诱导的脾脏B母细胞或大量淋巴结细胞发生反应。当用于脾脏切片染色时,N418在T细胞依赖区对树突状细胞进行染色,很像在这些融合实验中产生的抗II类单克隆抗体。此外,N418揭示了位于红髓和白髓之间边缘区巨噬细胞边缘的树突状细胞巢。这种定位将大多数树突状细胞定位在动脉血管和T细胞进入白髓的区域。我们得出结论,p150,90异二聚体是脾脏树突状细胞的主要β2整合素,并且我们推测它可能起到将这些抗原呈递细胞定位在允许接触静息T细胞再循环池的位点的作用。